ZAI LAB LIMITED Deferred Tax Assets, Operating Loss Carryforwards
ZAI LAB LIMITED (ZLAB) had Deferred Tax Assets, Operating Loss Carryforwards of $349.12 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-02-26
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $349.12M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $321.07M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $295.31M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $241.40M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards | Deferred Tax Assets, Operating Loss Carryforwards as first filed |
|---|---|---|
| 2025-12-31 | $349.12M 10-K · filed 2026-02-26 | |
| 2024-12-31 | $321.07M 10-K · filed 2026-02-26 | |
| 2023-12-31 | $295.31M 10-K · filed 2025-02-27 | |
| 2022-12-31 | $241.40M 10-K · filed 2024-02-27 | |
| 2021-12-31 | $175.10M 10-K · filed 2023-03-01 | |
| 2020-12-31 | $94.95M 10-K · filed 2023-03-01 | |
| 2020-06-30 | $102.58M 6-K · filed 2020-09-11 | |
| 2019-12-31 | $62.83M 10-K · filed 2022-03-01 | |
| 2018-12-31 | $49.73M 10-K · filed 2021-03-01 | $49.73M 20-F · filed 2019-03-29 |
| 2017-12-31 | $17.07M 20-F · filed 2020-04-29 | $17.08M 20-F · filed 2018-04-30 |
| 2016-12-31 | $8.09M 20-F · filed 2019-03-29 | |
| 2015-12-31 | $1.73M 20-F · filed 2018-04-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |